X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PRAX-222 is an ASO designed to selectively decrease SCN2A gene expression, directly targeting the underlying cause of early-seizure-onset SCN2A-DEE to treat seizures and other symptoms in patients with gain-of-function SCN2A mutations.
Lead Product(s): PRAX-222
Therapeutic Area: Genetic Disease Product Name: PRAX-222
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Invitae
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
The prodrug PRX-P4-003 serves as a substrate of pancreatic lipase, an enzyme whose biological activity is almost entirely restricted to the gut and thus is not expected to be activated by parenteral routes.
Lead Product(s): PRX-P4-003
Therapeutic Area: Psychiatry/Psychology Product Name: PRX-P4-003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
PRX-P4-003 is a new chemical entity (US Patent 10,662,146) designed by Praxis to be an abuse resistant, once-a-day medicine to treat apathy caused by Alzheimer’s disease as well as other diseases requiring dopaminergic stimulant activity.
Lead Product(s): PRX-P4-003
Therapeutic Area: Psychiatry/Psychology Product Name: PRX-P4-003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.9 million Upfront Cash: Undisclosed
Deal Type: Funding August 05, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
